Double-targeted immune cells take on hard-to-treat blood cancers
NCT ID NCT04186520
First seen Feb 24, 2026 · Last updated Jun 15, 2026 · Updated 15 times
Summary
This study tests a new type of CAR-T cell therapy that targets two proteins (CD19 and CD20) on cancer cells. It is for adults with B cell cancers like lymphoma or leukemia that have come back or not responded to prior treatments. The goal is to see if this therapy is safe and effective, and to explore a flexible way to manufacture the cells.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B CELL LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Medical College of Wisconsin and Froedtert Hospital
RECRUITINGMilwaukee, Wisconsin, 53226, United States
Contact Email: •••••@•••••
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.